What changed in Gilead Sciences, Inc.'s latest annual report
In the year ended 31 Dec 2025, Gilead Sciences, Inc.'s revenue rose 2.4% to USD 29.44bn, from USD 28.75bn; net income rose 1672.9% to USD 8.51bn, from USD 480.00m; shareholders' equity rose 17.4% to USD 22.70bn, from USD 19.33bn.
Year ended 31 Dec 2025. Source: 10-K filed 24 Feb 2026, read it on SEC EDGAR.
USD 28.75bn to USD 29.44bn
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Revenue | 28.75bn | 29.44bn | Up 2.4% |
| Net income | 480.00m | 8.51bn | Up 1672.9% |
| Total assets | 58.99bn | 59.02bn | Unchanged |
| Long-term debt | 24.90bn | 22.13bn | Down 11.1% |
| Shareholders' equity | 19.33bn | 22.70bn | Up 17.4% |
Questions people ask
Did Gilead Sciences, Inc.'s revenue grow last year?
Revenue grew 2.4%, from USD 28.75bn to USD 29.44bn in the year ended 31 Dec 2025.
Is Gilead Sciences, Inc. profitable?
Yes. Net income was USD 8.51bn in the year ended 31 Dec 2025. The year before: USD 480.00m.
How much cash and debt does Gilead Sciences, Inc. have?
At its latest year end (31 Dec 2025), Gilead Sciences, Inc. reported long-term debt of USD 22.13bn.
Where do these numbers come from?
From Gilead Sciences, Inc.'s own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with Gilead Sciences, Inc.?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Biological Products, (No Diagnostic Substances) companies
- Amgen Inc.Net income up 88.5%
- Moderna, Inc.Revenue down 39.9%
- Revolution Medicines, Inc.Total liabilities up 146.7%
- Biogen Inc.Net income down 20.8%
- Exelixis IncCash and cash equivalents up 122%
- Neurocrine Biosciences IncCash and cash equivalents up 206%
- Halozyme Therapeutics, Inc.Shareholders' equity down 86.6%
- Repligen CorpCash and cash equivalents down 25.3%